Tonix highlights TONMYA fibromyalgia launch, pipeline progress in investor presentation
TNXP•TONMYA launch and commercial ramp
Tonix investor presentation highlighted TONMYA’s commercial ramp, citing $11 million net sales in 2Q’26.
Total net product revenue reached $13.5 million in 2Q’26, supported by 12,592 prescriptions and 197% growth versus Q1’26.
Balance sheet and pipeline priorities
Cash and cash equivalents totaled $176.2 million at June 30, 2026, with no debt; runway is expected into early Q2’27.
Pipeline priorities include an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention targeted for 1Q’27.
TNX-102 SL label expansion programs include a potentially pivotal Phase 2 study in major depressive disorder; Phase 2 topline data are expected mid-2027.
